BioCentury | Apr 3, 2020
Deals

Servier adds mAb platform via takeout of former European biotech darling Symphogen

What was once a high-profile European biotech is now going out quietly as Servier is acquiring Danish mAb company Symphogen A/S for an undisclosed sum. The two companies are partnered across three clinical stage immuno-oncology...
BC Extra | Sep 3, 2019
Company News

Management tracks: Tempus brings on former FDA chief of staff; plus Bayer, Genfit, Accent and more

Lauren Silvis has joined personalized medicine company Tempus Labs Inc. (Chicago, Ill.) as SVP of external affairs. Silvis was FDA chief of staff from May 2017 to June 2019; she also served for two years...
BioCentury | May 24, 2019
Finance

How Europe’s hotspots of innovation could fuel its rise as a global player in new modalities

It is clear that Europe has hotspots of innovation that are discovering and developing the next wave of new therapeutic modalities. Nearly every category of new modality has a European champion, with clusters forming around...
BC Extra | May 15, 2019
Financial News

May 15 Financial Quick Takes: Perceptive leads $60M round for ArcherDx; plus Applied Therapeutics’ IPO, IsoPlexis, Symphogen

ArcherDx completes $60M series B  New investor Perceptive Advisors led a $60 million series B round for ArcherDx Inc. (Boulder, Colo.) that the company plans to use to scale operations, advance its companion diagnostic program...
BC Extra | Nov 30, 2018
Company News

Management tracks: Inflazome, Clementia

Two weeks after raising €40 million ($45.7 million) in a series B round in preparation for its first clinical trials which are slated for next year, Inflazome Ltd. (Dublin, Ireland) hired Thomas Jung as its...
BC Extra | Sep 5, 2018
Company News

Management tracks: Agios, Radius

Agios Pharmaceuticals Inc. (NASDAQ:AGIO) said David Schenkein will step down as CEO and become executive chairman, effective Feb. 1, 2019. He will succeed Chairman John Maraganore, who is also CEO at Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY)....
BC Innovations | Jun 14, 2018
Tools & Techniques

Imaging immunotherapy

Stanford University researchers have made an imaging agent that detects activated T cells and could predict whether a patient will respond to immunotherapy within days of treatment. Typically, it takes weeks to months to determine...
BioCentury | May 18, 2018
Finance

China comes to Europe

  The historically underfunded European biotech sector is in the early stages of tapping into a new stream of capital thanks to the explosion of biomedical innovation in China, which has spawned a wave of...
BC Week In Review | Apr 20, 2018
Company News

Servier to gain Shire's cancer business, Oncaspar for $2.4B

Shire plc (LSE:SHP; NASDAQ:SHPG) said it will sell its cancer business, including acute lymphoblastic leukemia (ALL) drug Oncaspar pegaspargase, to Servier (Suresnes, France) for $2.4 billion in cash. In addition to Oncaspar, Servier will gain...
BC Extra | Apr 16, 2018
Company News

Servier to gain Shire's cancer business, Oncaspar for $2.4B

Shire plc (LSE:SHP; NASDAQ:SHPG) said it will sell its cancer business, including acute lymphoblastic leukemia (ALL) drug Oncaspar pegaspargase, to Servier (Suresnes, France) for $2.4 billion in cash. In addition to Oncaspar, Servier will gain...
Items per page:
1 - 10 of 110
BioCentury | Apr 3, 2020
Deals

Servier adds mAb platform via takeout of former European biotech darling Symphogen

What was once a high-profile European biotech is now going out quietly as Servier is acquiring Danish mAb company Symphogen A/S for an undisclosed sum. The two companies are partnered across three clinical stage immuno-oncology...
BC Extra | Sep 3, 2019
Company News

Management tracks: Tempus brings on former FDA chief of staff; plus Bayer, Genfit, Accent and more

Lauren Silvis has joined personalized medicine company Tempus Labs Inc. (Chicago, Ill.) as SVP of external affairs. Silvis was FDA chief of staff from May 2017 to June 2019; she also served for two years...
BioCentury | May 24, 2019
Finance

How Europe’s hotspots of innovation could fuel its rise as a global player in new modalities

It is clear that Europe has hotspots of innovation that are discovering and developing the next wave of new therapeutic modalities. Nearly every category of new modality has a European champion, with clusters forming around...
BC Extra | May 15, 2019
Financial News

May 15 Financial Quick Takes: Perceptive leads $60M round for ArcherDx; plus Applied Therapeutics’ IPO, IsoPlexis, Symphogen

ArcherDx completes $60M series B  New investor Perceptive Advisors led a $60 million series B round for ArcherDx Inc. (Boulder, Colo.) that the company plans to use to scale operations, advance its companion diagnostic program...
BC Extra | Nov 30, 2018
Company News

Management tracks: Inflazome, Clementia

Two weeks after raising €40 million ($45.7 million) in a series B round in preparation for its first clinical trials which are slated for next year, Inflazome Ltd. (Dublin, Ireland) hired Thomas Jung as its...
BC Extra | Sep 5, 2018
Company News

Management tracks: Agios, Radius

Agios Pharmaceuticals Inc. (NASDAQ:AGIO) said David Schenkein will step down as CEO and become executive chairman, effective Feb. 1, 2019. He will succeed Chairman John Maraganore, who is also CEO at Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY)....
BC Innovations | Jun 14, 2018
Tools & Techniques

Imaging immunotherapy

Stanford University researchers have made an imaging agent that detects activated T cells and could predict whether a patient will respond to immunotherapy within days of treatment. Typically, it takes weeks to months to determine...
BioCentury | May 18, 2018
Finance

China comes to Europe

  The historically underfunded European biotech sector is in the early stages of tapping into a new stream of capital thanks to the explosion of biomedical innovation in China, which has spawned a wave of...
BC Week In Review | Apr 20, 2018
Company News

Servier to gain Shire's cancer business, Oncaspar for $2.4B

Shire plc (LSE:SHP; NASDAQ:SHPG) said it will sell its cancer business, including acute lymphoblastic leukemia (ALL) drug Oncaspar pegaspargase, to Servier (Suresnes, France) for $2.4 billion in cash. In addition to Oncaspar, Servier will gain...
BC Extra | Apr 16, 2018
Company News

Servier to gain Shire's cancer business, Oncaspar for $2.4B

Shire plc (LSE:SHP; NASDAQ:SHPG) said it will sell its cancer business, including acute lymphoblastic leukemia (ALL) drug Oncaspar pegaspargase, to Servier (Suresnes, France) for $2.4 billion in cash. In addition to Oncaspar, Servier will gain...
Items per page:
1 - 10 of 110